About Transgenic
Transgenic is a publicly listed company based in Kobe (Japan) founded in 2000. Genomics, CRO, and pathological diagnosis services are provided by Transgenic. The company has 241 employees. Its focus areas include Life Sciences, Genomics, Genomics Research and Research Models.
Company details
Transgenic was founded in 2000 in Kobe, Japan, within the biotechnology sector. CRO services are offered, including in-vitro assays for diseases such as Parkinsons and Alzheimers, alongside in-vivo testing with genetically engineered mice, small animals, and primates. Genomics operations encompass knock-out, knock-in, and transgenic mouse models produced via CRISPR-Cas9 technology. Antibody production utilizes GANP methods, while gene analysis and histopathological diagnosis services are also available.
- Headquarters Kobe, Japan
- Employees 241
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website transgenic.co.jp
- Social X
- Legal Name Trans Genic Group Inc.
- Annual Revenue$82.57 M (USD)1.3as on Mar 31, 2026
- Net Profit-$484.46 K (USD)92.91as on Mar 31, 2026
- EBITDA$1.84 M (USD)as on Mar 31, 2026
- Employee Count241
IPO & Listings of Transgenic
Transgenic is a publicly listed company on the TSE with ticker symbol 2342 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date10 Dec 2002
- Listed onTSE: 2342
- Listed entityTRANS GENIC GROUP INC.
- Exchange sectorHealth technology
- ISINJP3635720000
- Share price230.00 JPY (-0.43% on the day) · 2026-10-14
- Market capitalisation3,896,211,926.00 JPY
- Price to earnings120.4
- EPS (diluted, trailing year)1.91 JPY
- Volume (last session)10,500
Financials of Transgenic
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 13.17B JPY | -77.3M JPY | 293.6M JPY |
| 2024 | 13.01B JPY | -1.09B JPY | -64.4M JPY |
| 2023 | 13.08B JPY | 4.1M JPY | 253.6M JPY |
| 2022 | 11.43B JPY | -409.7M JPY | 158.4M JPY |
| 2021 | 12.58B JPY | 1.88B JPY | 2.07B JPY |
Detailed financial statements for Transgenic
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Transgenic
The website of Transgenic (transgenic.co.jp) receives about 3.7K visits a month and ranks #3,798,437 among all websites worldwide, #4,858 in Biotechnology and Pharmaceuticals.
- Monthly visits3.7K
▼ 7.8% vs previous month
- Unique visitors1.4K
per month
- Global rank#3,798,437
among all websites
- Category rank#4,858
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit2.7
- Average visit1 min 41 sec
- DevicesDesktop 30% · Mobile 70%
Websites whose visitors overlap most with Transgenic. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
cyagen.jp | cyagen.jp | 100% | #2,280,464 | – | |
jax.or.jp | jax.or.jp | 95% | #2,233,935 | – | |
| transgenic-group.co.jp | 92% | 5.4K | #2,345,414 | View details | |
wakenyaku.co.jp | wakenyaku.co.jp | 86% | #545,917 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Transgenic
Complete news archive for Transgenic
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Transgenic
Transgenic was founded in 2000.
Transgenic is headquartered in Kobe, Japan. It is registered at Kobe, Hyogo, Japan.
Transgenic has 241 employees.
Annual revenue of Transgenic is $82.57M as on Mar 31, 2026.
Transgenic was founded in 2000 in Kobe, Japan, within the biotechnology sector. CRO services are offered, including in-vitro assays for diseases such as Parkinsons and Alzheimers, alongside in-vivo testing with genetically engineered mice, small animals, and primates. Genomics operations encompass knock-out, knock-in, and transgenic mouse models produced via CRISPR-Cas9 technology. Antibody production utilizes GANP methods, while gene analysis and histopathological diagnosis services are also available.
Yes, Transgenic is publicly traded on TSE under the ticker symbol 2342.